Natural history of KIF1A associated neurological disorder

Active Grant Awarded

Award ID
R01FD008873
Recipient
Awarding agency
Obligated
$599,239

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 4% complete
Funding agency
Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services Food and Drug Administration awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $599,239 on September 23, 2026, under Food and Drug Administration Research (CFDA 93.103). Grant R01FD008873 funds a natural history study of KIF1A-associated neurological disorder (KAND), a rare neurodevelopmental and neurodegenerative condition, to identify phenotypic endpoints for future FDA trials. Aim 1 abstracts neurodevelopmental, motor, cognitive, vision, seizure/EEG, brain imaging, and quality-of-life data from medical records and online questionnaires for at least 200 patients. Aim 2 conducts longitudinal in-person assessments of cognitive and motor function, vision and optic nerve atrophy, quantitative EEG, and blood-based neuronal degeneration biomarkers in 60 patients. Aim 3 validates a remote assessment battery with longitudinal measures from at least 60 patients. Patients are enrolled and characterized by genotype in partnership with KIF1A.org, a patient advocacy organization devoted to KAND. The award is an assistance grant with a place of performance in Boston, Massachusetts 02115, and an ultimate completion date of August 31, 2030.

Description

Abstract
KIF1A-associated neurological disorder (KAND) is a rare, highly phenotypically heterogeneous neurodevelopmental and neurodegenerative condition caused by heterozygous mutations in the KIF1A gene. While there are no current FDA approved disease-modifying therapies for KAND, we have an N-of-1 treatment for the first KAND patient using a gapmer ASO that shows great promise. Due to the design of the ASO (targeting a common polymorphism in CIS with the mutation), approximately 25% of KAND patients could be treated with the same ASO. To extend this treatment to other patients, the natural history of the disease, by genotype, must be studied longitudinally to identify robust, sensitive outcome measures. We have preliminary data from 311 patients, largely based on cross-sectional online questionnaire data, demonstrating that clinical severity and disease course are mutation-dependent. By partnering with KIF1A.ORG, a large patient advocacy partner devoted to KAND, we will enroll and characterize patients by genotype to establish phenotypic course, and select phenotypic endpoints for future FDA trials. This will be done with three aims. Aim 1. We will characterize the natural history of KAND with data abstracted from medical records and online questionnaires. These data include neurodevelopmental, motor and cognitive function, vision/optic nerve atrophy, seizures/electroencephalograms (EEGS), brain imaging, and quality of life in at least 200 patients. Aim 2. We will characterize the natural history of KAND with longitudinal in-person assessments. This will be done in 60 patients using gold-standard assessments of cognitive function, motor function, vision/optic nerve atrophy, and quantitative EEG and blood-based biomarkers of neuronal degeneration. Aim 3. We will validate a remote assessment battery with longitudinal measures. Remote data collection from at least 60 patients will include cognitive and speech/language assessments, parental reports, actigraphy biosensors, and number of falls. The same patients will be assessed in aims 2 and 3 so that we can validate the remote measures. In all aims, clinical severity and disease progression will be analyzed by KIF1A genotype incorporating single molecule in vitro phenotype. We will build analytical models to predict clinical trajectories. These natural history studies will define the course of disease and its severity, particularly in relation to specific mutations, guiding design of clinical trials for KAND. Additionally, validation of remote assessments can be applied to other neurogenetic disorders. We will seek funding through NIH grant mechanisms (R01 and U01) for KAND ASO trials.

Quick answers

Who received award R01FD008873?

R01FD008873 was awarded to The Children's Hospital Corporation by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award R01FD008873 worth?

$599,239 has been obligated on R01FD008873.

Which agency awarded R01FD008873?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008873, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award